San Diego biotech plans to launch $69M IPO

08/15/2013 | San Diego Union-Tribune · Xconomy

Fate Therapeutics could secure as much as $69 million from an initial public offering, according to an SEC filing. The San Diego-based firm plans to use the money to further develop ProHema, its umbilical cord blood-based product designed to enhance the success of bone marrow transplants, and other preclinical-stage products, and for other corporate purposes.

View Full Article in:

San Diego Union-Tribune · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC